Publications for all Oxford Principal Investigators within the CAMS Oxford Institute are included here, please use the search functions for publications related to specific Principal Investigators.
Editorial: Beyond protein degradation and lysine modification: novel insights into non-canonical ubiquitination
Sapmaz A. et al, (2024), Frontiers in Molecular Biosciences, 11
Deubiquitinases in muscle physiology and disorders
Olie CS. et al, (2024), Biochemical Society Transactions, 52, 1085 - 1098
Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1
Imhoff RD. et al, (2024), Journal of Medicinal Chemistry, 67, 4496 - 4524
Structural basis for SMAC-mediated antagonism of caspase inhibition by the giant ubiquitin ligase BIRC6
Dietz L. et al, (2023), Science, 379, 1112 - 1117
Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule Benzosulfonamides
O’Brien DP. et al, (2022)
Comprehensive Landscape of Active Deubiquitinating Enzymes Profiled by Advanced Chemoproteomics
Pinto-Fernández A. et al, (2019), Frontiers in Chemistry, 7
Deacetylation Inhibition Reverses PABPN1-Dependent Muscle Wasting
Olie CS. et al, (2019), iScience, 12, 318 - 332
Human Platelet Protein Ubiquitylation and Changes following GPVI Activation
Unsworth A. et al, (2019), Thrombosis and Haemostasis, 119, 104 - 116
A Linear Diubiquitin-Based Probe for Efficient and Selective Detection of the Deubiquitinating Enzyme OTULIN
Weber A. et al, (2017), Cell Chemical Biology, 24, 1299 - 1313.e7
Molecular basis of USP7 inhibition by selective small-molecule inhibitors
Turnbull AP. et al, (2017), Nature, 550, 481 - 486
DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets
Pinto-Fernandez A. and Kessler BM., (2016), Frontiers in Genetics, 7